Date:5/26/2010

certainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to secure and enforce patent rights for its proprietary extraction methods, successfully develop and commercialization of its Schisandra-based drugs, ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    For more information, please contact:

    Company Contact:
     Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-5392-5461
     Email: ir@renhuang.com


     CCG Investor Relations:
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com

     Ms. Lei Huang, Account Manager
     Phone: +1-646-833-3417 (New York)
  
'/>"/>
SOURCE  Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related medicine technology :

1. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 107th China Import and Export Fair
2. Renhuang Elected as Deputy Chair Unit of Heilongjiang Medical Association
3. Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
4. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
5. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
6. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
7. Renhuang Announces Price Increase on Shengmai Granules
8. Renhuang Announces Fiscal Year 2010 Guidance
9. FDA Announces Collaboration With Drugs.com
10. VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010
11. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain